Abstract
This chapter discusses systemic medicines that modulate the immune system, with the rationale that some cases of IC/BPS involve an inflammatory pathophysiology. Due to the significant risks of systemic immune suppression, it is essential to select patients who have the relevant pathophysiology. With current technology, this is best accomplished by cystoscopy and bladder biopsy. It also is essential to try less risky treatments first, and offer immunomodulation only when the less risky treatments fail. Of all immunomodulators previously studied for IC/BPS, only two are discussed in the American Urological Association guideline. First, the guideline recommends that long-term systemic glucocorticoids not be used. Second, the guideline lists cyclosporine A as a fifth tier treatment option (with the sixth and final tier being major surgery). This chapter summarizes the prior literature on immunomodulators previously investigated for IC/BPS and describes practical considerations for clinical use of cyclosporine A.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hunner GL. A rare type of bladder ulcer in women: report of cases. Boston Med Surg J. 1915;172:660–4.
Hunner GL. Elusive ulcer of the bladder. Further notes on a rare type of bladder ulcer, with a report of twenty-five cases. Am J Obstet. 1918;78:374.
Hunner GL. A rare type of bladder ulcer. Further notes, with a report of eighteen cases. JAMA. 1918;70:203–12.
Burford EH, Burford CE. Hunner ulcer of the bladder: a report of 187 cases. J Urol. 1958;79:952–5.
Walsh A. Historical perspectives. In: Hanno PM, Staskin DR, Krane RJ, Wein AJ, editors. Interstitial cystitis. New York, NY: Springer; 1990. p. 17–21.
Walsh A. Interstitial cystitis. In: Harrison JH, Gittes RF, Perlmutter AD, Stamey TA, Walsh PC, editors. Campbell’s urology. 4th ed. Philadelphia, PA: WB Saunders; 1978. p. 693–707.
Hand JR. Interstitial cystitis; report of 223 cases (204 women and 19 men). J Urol. 1949;61:291–310.
Fall M, Johansson SL, Aldenborg F. Chronic interstitial cystitis: a heterogeneous syndrome. J Urol. 1987;137:35–8.
Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990;143:1118–24.
van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–7.
Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg Jr L, Payne CK, Wesselmann U, Faraday MM, Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70.
Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–53.
Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186:540–4.
Wyndaele JJ, Van Dyck J, Toussaint N. Cystoscopy and bladder biopsies in patients with bladder pain syndrome carried out following ESSIC guidelines. Scand J Urol Nephrol. 2009;43:471–5.
Erickson DR, Tomaszewski JE, Kunselman AR, Setter CM, Peters KM, Rovner ES, Demers LM, Wheeler MA, Keay SK. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J Urol. 2008;179:1850–6.
Andersson K-E, Hedlund H. Pharmacotherapeutic goals in interstitial cystitis. In: Hanno PM, Staskin DR, Krane RJ, Wein AJ, editors. Interstitial cystitis. New York: Springer; 1990. p. 135–45.
Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner's ulcer subtype interstitial cystitis. Can J Urol. 2009;16:4536–40.
Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol. 2005;173:841–3.
Hosseini A, Ehren I, Wiklund NP. Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis. J Urol. 2004;172:2261–5.
Oravisto KJ, Alfthan OS. Treatment of interstitial cystitis with immunosuppression and chloroquine derivatives. Eur Urol. 1976;2:82–4.
Moran PA, Dwyer PL, Carey MP, Maher CF, Radford NJ. Oral methotrexate in the management of refractory interstitial cystitis. Aust N Z J Obstet Gynaecol. 1999;39:468–71.
Yang CC, Burks DA, Propert KJ, Mayer RD, Peters KM, Nickel JC, Payne CK, FitzGerald MP, Hanno PM, Chai TC, Kreder KJ, Lukacz ES, Foster HE, Cen L, Landis JR, Kusek JW, Nyberg LM, Interstitial Cystitis Collaborative Research Network. Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol. 2011;185:901–6.
Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191:77–82.
Foster Jr HE, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, Yang CC, Chai TC, Kreder KJ, Peters KM, Lukacz ES, FitzGerald MP, Cen L, Landis JR, Propert KJ, Yang W, Kusek JW, Nyberg LM, Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183:1853–8.
Forsell T, Ruutu M, Isoniemi H, Ahonen J, Alfthan O. Cyclosporine in severe interstitial cystitis. J Urol. 1996;155:1591–3.
Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171:2138–41.
Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, Ruutu M. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174:2235–8.
Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188:1186–91.
Ehrén I, Hallén Grufman K, Vrba M, Sundelin R, Lafolie P. Nitric oxide as a marker for evaluation of treatment effect of cyclosporine A in patients with bladder pain syndrome/interstitial cystitis type 3C. Scand J Urol. 2013;47:503–8.
Sairanen J, Tammela TL, Ruutu M. Tacrolimus in the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC): a pilot study. Eur Urol Suppl. 2010;9(2):212.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Erickson, D.R., Blalock, E.M. (2017). Immunomodulators for Interstitial Cystitis/Bladder Pain Syndrome. In: Moldwin, R. (eds) Urological and Gynaecological Chronic Pelvic Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-48464-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-48464-8_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-48462-4
Online ISBN: 978-3-319-48464-8
eBook Packages: MedicineMedicine (R0)